Articles tagged with Myeloid Leukemia
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Onconova Therapeutics presents updated clinical trial results for Estybon (ON 01910.Na) in patients with myelodysplastic syndromes, showing increases in overall survival and bone marrow blast responses. Additionally, ON 013105, a Cyclin D1 inhibitor, demonstrates efficacy in nonclinical models of mantle cell lymphoma.
Researchers found a common genetic alteration in AML patients who died quickly from the disease. DNMT3A mutations were associated with poor survival rates, and patients with these mutations may benefit from aggressive treatment such as bone marrow transplantation.
Researchers discovered a key mutation in the DNA methyltransferase 3A gene that affects AML treatment prognosis, leading to significantly shorter survival times for patients with the mutation. The study's findings suggest that treating patients with this mutation aggressively may improve their outcomes.
For nearly three-quarters of elderly patients, intensive chemotherapy is associated with poor prognosis and low median survival time. Researchers identified several predictive factors for mortality rate, including age over 80, genetic abnormalities, and kidney function impairment.
Researchers identified Musashi 2 as a predictive marker for prognosis in AML and CML patients. High levels of Musashi 2 associated with increased cell proliferation, decreased maturation, and aggressive cancer behavior.
Scientists found that p53 loss enables aberrant self-renewal of myeloid precursors, leading to acute myeloid leukemia. In experiments with living mice, the team demonstrated that a combination of p53 and Kras mutations confers resistance to chemotherapy and promotes aggressive AML.
Researchers identify GRP78 as key factor in mucormycosis pathogenesis, providing new avenue for therapeutics development. PET probes detect distinct immune cell populations, suggesting wider use for immune modulating therapies.
Dr. James Bogenberger has been awarded a 3-year fellowship to research acute myeloid leukemia at TGen, with the goal of identifying therapeutic targets that sensitize AML to epigenetic therapies. The fellowship project aims to translate state-of-the-art biomedical research into novel targeted therapy approaches for leukemia patients.
The study found a strong association between the Human Development Index and rates of stem cell transplantation for acute myeloid leukemia patients. Countries with higher HDI scores had significantly better outcomes, including reduced risk of relapse and improved leukemia-free survival.
Researchers at Ohio State University have discovered a new molecular network that contributes to abnormal KIT protein abundance in acute leukemia cells. Targeting this network with therapeutic drugs may prove more effective than current standard of care.
Researchers at Boston Children's Hospital discovered a possible way to kill off leukemia stem cells and prevent relapse. The study found that targeting the Wnt/beta-catenin pathway can suppress leukemia recurrence by inhibiting beta-catenin, a crucial player in leukemia stem cell development.
Researchers have identified a distinct type of mutation in acute myeloid leukemia patients that could account for half of the remaining cases. The mutations lead to increased production of a molecule called 2HG, which may block the ability of leukemic cells to differentiate into normal blood cells.
A study found that mutations in IDH1 enzyme result in excess production of 2-HG, a metabolite common among cancers including leukemia and brain tumors. Elevated serum levels of 2-HG were detected in approximately 8% of AML patients with these mutations.
A study led by Dr. Tarik Möröy discovered a link between a gene variant and acute myeloid leukemia (AML), a subtype of blood cancer. The GFI136N variant is associated with a 60% higher risk of developing AML, making it a potential biomarker for evaluating prognosis in patients.
A study published in Cancer Cell reveals that epigenetic differences can distinguish patients with acute myeloid leukemia (AML) into subtypes with varying responsiveness to therapy. A set of 15-gene DNA methylation biomarkers was found to be highly predictive of patient survival.
A new study has found that long-duration exposure to formaldehyde used in embalming practices is associated with an increased risk of death from myeloid leukemia. The study, published in the Journal of the National Cancer Institute, also found no associations with other lymphohematopoietic malignancies.
A new study finds that spleen tyrosine kinase (Syk) is a promising therapeutic target for acute myeloid leukemia (AML). The research integrates genetic and proteomic approaches to identify Syk as a potential treatment option.
A comprehensive analysis of childhood acute myeloid leukemia (AML) found only a few genetic mistakes contributing to the disease. The study, published in the Proceedings of the National Academy of Sciences, highlights the need for more detailed examination of AML's complete genome.
Researchers have discovered a protein on the surface of leukemia stem cells that helps them evade macrophage immune cells. Targeting this protein, called CD47, may help increase the body's appetite for killing cancer cells.
Researchers analyzed 24 clinical trials involving over 6,000 AML patients to find that donor stem cell transplant (SCT) in first remission significantly improves survival and reduces disease relapse for those with intermediate-risk disease. This approach is now considered the preferred treatment for this group.
Allogeneic stem cell transplantation provides significant overall and relapse-free survival benefits for adult patients with intermediate- and poor-risk acute myeloid leukemia in first complete remission. However, its benefit varies by cytogenetic risk, with no significant advantage for good-risk AML.
A new study found that boosting miR-29b levels in acute myeloid leukemia cells reverses gene changes, enabling the cells to differentiate and mature. This process could lead to a drop in global DNA methylation and reactivation of tumor suppressor genes, offering a potential treatment for AML.
Researchers developed mouse models of human acute myeloid leukemia (AML) that accurately predict response to chemotherapy and identify key genes promoting resistance or sensitivity. These models provide valuable insights into AML's genetic heterogeneity and may help redesign therapy for maximum benefit.
A new study published in The Lancet Oncology found that azacitidine significantly improves the survival of patients with high-risk forms of myelodysplastic syndromes (MDS). Patients treated with azacitidine had a median overall survival of 24.5 months, compared to 15 months for those receiving conventional care.
Patients with acute myeloid leukemia who received VIDAZA had significantly increased overall survival compared to those treated with conventional care regimens. Approximately half of the AML patients treated with VIDAZA survived at least two years, compared to just 16% of those receiving conventional chemotherapy.
A subset analysis of the AZA-001 trial demonstrated that Vidaza significantly improved overall survival in patients with WHO-defined acute myeloid leukemia (AML) compared to conventional care regimens. The study also showed reduced infections, hospitalizations, and red blood cell transfusions.
Researchers at Ohio State University found that acute myeloid leukemia (AML) patients with mutations in the RAS gene are more likely to be cured when treated with high doses of cytarabine. Testing for RAS mutations may help doctors identify which AML patients should receive this therapy.
Scientists at Cincinnati Children's Hospital Medical Center have discovered that the microenvironment of blood-forming tissues plays a critical role in promoting leukemia progression and determining disease type in mixed lineage leukemias (MLL). The study, which used human-based MLL models in mice, suggests that disrupting the protein ...
Researchers discovered a link between microRNA levels and the risk of relapse in acute myeloid leukemia (AML) patients. The study found that abnormal microRNA patterns were associated with an increased risk of recurrence, providing new insights into possible causes of the disease.
Researchers found a link between low microRNA levels and high gene activity in AML, suggesting new therapeutic targets. The study identified two genes in the Hox family that are over-active in leukemia cells, providing new insights into AML treatment.
New research reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity. Additionally, studies on cardiac development and wound healing have identified novel genes and mechanisms, offering potential therapeutic targets for chronic viral infections and cutaneous wounds.
Researchers at MD Anderson Cancer Center report a new kidney cancer drug that targets the FLT3-ITD mutation in AML, reducing leukemia cells by 90% in patients. The drug has shown minimal side effects and is being tested in combination with chemotherapy.
Researchers found that the N-Myc gene triggers cancer when paired with growth-promoting protein IL-3 and causes cell suicide without it. The study also shows that immortalized cells overexpressing N-Myc become more aggressive and produce fewer growth-inhibiting proteins.
A new study suggests that acute leukemia patients with a specific genetic mutation may benefit from aggressive therapy to extend their disease-free survival. Researchers found that treating patients with the MLL-PTD mutation with an autologous stem cell transplant significantly reduced early relapses.
A new study by Ohio State University researchers links high ERG gene activity to a more lethal subtype of acute myeloid leukemia (AML). Patients with high ERG expression are almost six times more likely to relapse or die within five years, highlighting the need for more intense therapy.
Researchers found that chronic myeloid leukemia stem cells have a high frequency of BCR-ABL gene mutations, even in the absence of imatinib, which could lead to drug resistance. This genetic instability may contribute to relapses and disease progression.
Most individuals with acute myeloid leukemia (AML) express CDX2, a protein regulating HOX family genes. Reducing CDX2 levels decreases AML cell proliferation, supporting its causal role in leukemogenesis.
A University of Minnesota study found that over 90% of children and young adults who survive five years or longer after diagnosis and treatment for acute myeloid leukemia (AML) are alive 20 years later. Regular health check-ups and monitoring are crucial to prevent late effects of cancer treatment.
Researchers have found that the experimental drug ABT-737 can destroy AML blast, progenitor and stem cells, potentially providing a new way to treat cancer. Combining ABT-737 with another agent may overcome resistance and improve treatment outcomes.
Researchers at the University of Pennsylvania School of Medicine have identified a new protein called Tribbles associated with acute myelogenous leukemia (AML). The study found that Tribbles induces AML by inactivating the C/EBPá protein, providing a potential therapeutic target.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.
A new study finds that hospice enrollment rates vary more by health center than individual patient characteristics. Additionally, a meta-analysis suggests that high processed meat consumption is associated with an increased risk of stomach cancer, while another study identifies a potential target for leukemia treatment and notes the pe...
Researchers found that STAT1 expression was lower in SCCHN tumors than in normal tissue, and increasing STAT1 expression led to suppressed tumor growth. The study also suggests that STAT1 works as a tumor suppressor for SCCHN cells, but when its expression is lowered, SCCHN tumors grow.
Researchers create conditional mouse model to study CBFB-SMMHC, a fusion protein linked to 12% of human AML cases. The model shows that CBFB-SMMHC induces abnormal preleukemic blood cell progenitors, leading to AML development in adult mice.
A new clinical trial found that using minimal residual disease (MRD) measurements, doctors can accurately assess treatment response and adjust therapy, leading to a high remission rate and low treatment-related mortality. This breakthrough approach improved outcomes for pediatric AML patients by identifying slow responders and intensif...
Recent studies have shown that treatment of chronic myeloid leukemia has improved significantly, with a focus on reducing residual disease through continued therapy and new treatment options. These advances have led to better prognosis for patients, providing substantial prolongation of normal life.
Researchers at Ohio State University discovered a new gene marker, ERG, that signals an aggressive form of acute myeloid leukemia (AML) requiring intensive therapy. High ERG activity is associated with poor relapse and survival rates in AML patients with normal cytogenetics.
A study found that AML patients with the 8;21 translocation have a poor response to treatment and are more likely to relapse. Nonwhite patients with this abnormality were almost six times less likely to achieve complete remission than whites.
Researchers at Ludwig Maximillians University report that AML1-ETO cooperates with FLT3 to induce rapid and aggressive acute leukemia in mice. This study supports a pathogenetic model of acute leukemia, which requires activating mutations in signal transduction pathways and transcription factors for leukemogenesis.
New research presented at the American Society of Hematology Annual Meeting reveals promising results for tipifarnib, a potential treatment for acute myeloid leukemia (AML) in elderly patients. The study found molecular predictors of response to tipifarnib, offering hope for improved patient outcomes.
Researchers have successfully demonstrated that half-matched donor (haploidentical) natural killer cells can survive and persist to actively attack cancer cells, potentially leading to remission and eligibility for bone marrow transplant. This breakthrough treatment option shows promise for some patients with AML.
Research suggests that more intense therapies lead to better remission rates and longer survival for adults with acute myeloid leukemia (AML) who have normal genetic makeup. Patients with an enlarged spleen are less likely to enter remission, highlighting the need for targeted treatment.
A recent study published in Cancer Epidemiology, Biomarkers and Prevention journal found that obesity is associated with a higher risk of acute myeloid leukemia (AML) in older women. The study followed over 37,000 Iowa women for 14 years and found that those who were overweight or obese had a 90% increased risk of developing AML compar...
A new analysis has found a link between breastfeeding and lower risks of both acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) in children. The study suggests that even short-term breastfeeding may be protective, particularly during the first few months.
A recent study led by Dr. Ardeshir Ghavamzadeh and Dr. Kamran Alimoghaddam found that arsenic achieved complete remission in over 90% of newly diagnosed APL patients. The treatment has also shown promising results in other cancers like multiple myeloma, with a mean survival time of nearly 34 months for most patients.
A new study reveals gene microarray technology can accurately diagnose acute myeloid leukemia subtypes, leading to better treatments. The signatures of gene expression identified in pediatric leukemias also apply to adult cases, improving diagnosis and treatment outcomes.
Researchers found that AML patients with abnormal chromosomes during remission are more likely to relapse and have a shorter survival. This suggests that routine testing for chromosomal abnormalities may be necessary to predict long-term outcomes in these patients.
A retrospective study of 110 elderly leukemia patients found similar complete remission and two-year survival rates as younger patients when treated with anthracyclin-based induction chemotherapy. The study's findings suggest that age is not a predictor of survival, but rather the treatment protocol received.
Researchers have identified two distinct patterns of gene activity that correlate with patient outcomes in intermediate-risk AML. The findings could lead to more personalized treatment approaches for patients with this type of cancer.
The calcium-sensing receptor plays a crucial role in regulating mammary gland function, influencing milk production and composition. This study demonstrates that the receptor helps match milk production with available calcium levels in the mother's body.